Glenmark Pharmaceuticals has announced that its partner Eli Lilly has suspended further clinical development for molecule GRC 6211 in Osteoarthritis pain. The molecule is used for a range of pain indications including osteoarthritis. Glenmark and Lilly are currently in discussions on the way forward, a company release to BSE said.
Under the terms of the agreement signed in Oct 2007, Lilly had acquired the rights to a portfolio of transient receptor potential vanilloid sub-family 1 (TRPV1) antagonist molecules, including GRC 6211 which was in early clinical Phase II development at the time.
The collaboration between Glenmark and Lilly covers all TRPV1 antagonist molecules discovered by either company.
